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Association between Postnatal Dexamethasone for Treatment
of Bronchopulmonary Dysplasia and Brain Volumes at Adolescence
in Infants Born Very Preterm
Jeanie L. Y. Cheong, MD1,2,3, Alice C. Burnett, PhD2, Katherine J. Lee, PhD2,4,5, Gehan Roberts, PhD4,6,
Deanne K. Thompson, PhD2,7,8, Stephen J. Wood, PhD9, Alan Connelly, PhD8, Peter J. Anderson, PhD2,4,
and Lex W. Doyle, MD1,2,3, for the Victorian Infant Collaborative Study Group*
Objectives To compare brain volumes in adolescents who were born extremely preterm (<28 weeks gestation)
who had received postnatal dexamethasone, and to determine if there was a postnatal dexamethasone dose–
response effect on brain volumes.
Study design Geographical cohort study of extremely preterm adolescents born in 1991-1992 in Victoria,
Australia. T1-weightedmagnetic resonance imaging was performed at 18 years of age. Segmented and parcellated
brain volumes were calculated using an automated segmentation method (FreeSurfer) and compared between
groups, with and without adjustment for potential confounders. The relationships between total postnatal dexa-
methasone dose and brain volumes were explored using linear regression.
Results Of the 148 extremely preterm participants, 55 (37%) had received postnatal dexamethasone, with a
cumulative mean dose of 7.7 mg/kg. Compared with participants who did not receive postnatal dexamethasone,
those who did had smaller total brain tissue volumes (mean difference 3.6%, 95% CI [7.0%, 0.3%], P value
= .04) and smaller white matter, thalami, and basal ganglia volumes (all P < .05). There was a trend of smaller total
brain and white matter volumes with increasing dose of postnatal dexamethasone (regression coefficient 7.7
[95% CI 16.2, 0.8] and 3.2 [6.6, 0.2], respectively).
Conclusions Extremely preterm adolescents who received postnatal dexamethasone in the newborn period had
smaller total brain tissue volumes than those who did not receive postnatal dexamethasone, particularly white mat-
ter, thalami, and basal ganglia. Vulnerability of brain tissues or structures associated with postnatal dexamethasone
varies by structure and persists into adolescence. (J Pediatr 2014;164:737-43).See editorial, p 687ostnatal corticosteroids (PCS) to prevent or treat bronchopulmonary dysplasia (BPD) in preterm infants have beneficialPeffects, such as earlier extubation and lower rates of BPD.1,2 However, PCS use, especially dexamethasone, has also beenassociated with adverse neurodevelopmental outcomes, in particular cerebral palsy.1
Experimental models have shown the vulnerability of the developing brain to corticosteroids, including exacerbation of
neuronal and astroglial injury in the hippocampus,3,4 and impaired neurogenesis, myelination, and brain cell division.5,6 ThereFrom the 1Neonatal Services, Royal Women’s Hospital;
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Research Fellowship 628371 [to P.A.], Early Careeris recent evidence suggesting that the newborn cerebellum may be at greater risk
than other structures in the brain given that it has the highest number of gluco-
corticoid receptors in the brain, localized to the external granular layer.7
Magnetic resonance imaging (MRI) allows the characterization of brain alter-
ations associated with preterm birth. Several studies in the last decade have
reported MRI-derived brain structural alterations associated with PCS, particu-
larly in total brain tissue, cortical graymatter, subcortical gray matter, hippocam-
pus, and cerebellum, which may relate to the neurodevelopmental deficits
reported in preterm children.8-14 The corticosteroids used in these previous
MRI studies were mainly dexamethasone and hydrocortisone, and MRI per-
formed at term-equivalent age, with the exception of 1 study whereMRI was per-
formed at 8 years of age.11 These small studies have not been able to conclusively
establish either a dose–response relationship or regional vulnerability withinFellowship 1053787 [to J.C.], Early Career Fellowship
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BPD Bronchopulmonary dysplasia
MRI Magnetic resonance imaging
PCS Postnatal corticosteroid
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THE JOURNAL OF PEDIATRICS  www.jpeds.com Vol. 164, No. 4either gray or white matter to corticosteroids. More impor-
tantly, there are no studies of alterations of long-term brain
volume in adolescence following PCS use. We sought to
address these research gaps in a large prospective longitudinal
cohort of extremely preterm (<28 weeks) survivors who had
a brain MRI at 18 years of age.
Specifically, the aims of this study were to compare the vol-
umes of multiple brain tissues and structures between
extremely preterm adolescents who had received postnatal
dexamethasone in the newborn period with those who did
not, and to determine whether there is a dose–response rela-
tionship of postnatal dexamethasone with brain volumes at
age 18 years. We also aimed a priori to explore regional
vulnerability within cortical gray and white matter if a group
difference was found in either of these brain tissues in the
initial analysis.
We hypothesized that extremely preterm adolescents who
had received postnatal dexamethasonewould have smaller to-
tal brain tissue volumes compared with those who had not, as
well as smaller volumes in cortical gray matter, basal ganglia
and thalami, cerebellum, and hippocampus as previously re-
ported at term-equivalent age.We expected there would be no
regional vulnerability within either cortical gray orwhitemat-
ter. We also hypothesized that higher cumulative postnatal
dexamethasone doses received in the newborn period would
be associated with smaller brain volumes at age 18 years.
Methods
Participants of this study were part of a geographic, prospec-
tive cohort of all extremely preterm infants born in the state
of Victoria, Australia, between January 1991 and December
1992 enrolled at birth. Study participants had been previ-
ously assessed at ages 2, 5, and 8 years.15-18 All participants
were invited to a health and developmental follow-up at
age 18 years, which included an MRI scan.
Ethical approval for the original and follow-up studies was
from the Human Research Ethics Committees of the Royal
Women’s Hospital, Mercy Hospital for Women, Monash
Medical Centre, and Royal Children’s Hospital, Melbourne.
Written consent was from all participants and their parents
if they were younger than 18 years of age at the time of assess-
ment.
Perinatal and neonatal data were collected prospectively
from medical records. Major brain injury (grade 3 or 4 intra-
ventricular hemorrhage or cystic periventricular leukomala-
cia) was diagnosed by serial cranial ultrasound during the
primary hospitalization. BPD was diagnosed in infants with
respiratory distress who were oxygen-dependent at 36 weeks
corrected gestational age. Corticosteroids to treat or prevent
BPD were prescribed at the discretion of the treating clini-
cians in each of the 4 tertiary level nurseries in the state of
Victoria. The primary corticosteroid prescribed was dexa-
methasone, either parenteral or oral, started after the first
week of life. Occasionally, doses of hydrocortisone were given
to infants if they were considered to be at increased risk of738adrenal failure during a time of crisis, such as surgery. As
hydrocortisone use was very uncommon, doses of hydrocor-
tisone were converted to dexamethasone equivalent doses
(assuming relative potencies of dexamethasone 25 and hy-
drocortisone 1) and we refer to postnatal dexamethasone
throughout the manuscript, which includes hydrocortisone.
Data on postnatal dexamethasone use were collected
throughout the complete neonatal stay in the neonatal nurs-
eries. The total dose in mg/kg was recorded.
MRI
MRI was performed at 2 of the study sites, each using a
Siemens 3TMAGNETOMTrioMRI system (Siemens, Erlan-
gen, Germany), a 12-channel receive-only head coil, and the
same acquisition protocol. For this study, three-dimensional
T1-weighted Magnetization Prepared Rapid Gradient Echo
datasets were obtained using the following measurements:
non-isotropic voxels 0.7  0.7  1.2 mm, field of view 230
mm, repetition time 1800 ms, echo time 2.67 ms, and flip
angle 9.
Image Analysis
MRI data were processed by a single operator, blinded to
group status, on Linux workstations using the automated
FreeSurfer image processing suite (stable release v. 5.0,
http://surfer.nmr.mgh.harvard.edu).19,20 Images were
excluded if they were considered of unacceptably poor qual-
ity because of artifact and those with significant structural ab-
normalities that precluded FreeSurfer registration. The
magnetic resonance images were visually inspected and
manually edited as required during the automated processing
pipeline.
The automated labeling system for whole brain segmenta-
tion within FreeSurfer was used and volumes were estimated
for cortical graymatter, whitematter, thalamus, caudate, puta-
men, pallidum, hippocampus, amygdala, cerebellar white and
graymatter, and intracranial volume (including the ventricular
volumes).20 The total volumes for caudate, putamen, and pal-
lidumwere presented individually and also combined to repre-
sent basal ganglia volume. Cerebellar volume was taken as the
sum of cerebellar white and graymatter. Total brain tissue vol-
ume was the combined volumes of all the above brain struc-
tures including the brainstem (ie, excluding cerebrospinal
fluid volume). Freesurfer’s 34 parcellated cortical gray matter
regions using the Desikan atlas21,22 were combined to form
20 neuroanatomical regions (Table I; available at www.jpeds.
com). Freesurfer estimates the volume for each brain tissue
or structure separately for each hemisphere with the
exception of intracranial volume, but for our analyses we
combined volumes from both hemispheres.
Statistical Analyses
Data were analyzed using STATA 12.0 (StatCorp, Houston,
Texas). Participant characteristics were compared between
participants with and without analyzable MRI, using t tests
or c2 analyses. Group differences in brain volumes wereCheong et al
Table II. Participant characteristics
Received
PCS (n = 55)
No PCS
(n = 93)
Multiple births 22 (23) 13 (24)
Gestational age at birth in wk, mean (SD) 25.3 (1.1) 26.2 (0.9)
Birthweight in g, mean (SD) 785 (145) 963 (160)
Birthweight #2 SD 3 (5) 1 (1)
Male 31 (56) 39 (42)
Antenatal corticosteroids 40 (73) 62 (67)
Major brain injury* 5 (9) 10 (11)
BPD† 36 (65) 21 (23)
Duration of PCS treatment in d, median (IQR) 27 (17-39) -
Total cumulative PCS dose in mg/kg, mean (SD) 7.9 (4.0) -
Day of life at PCS commencement, mean (SD) 23.9 (7.7) -
Corrected age at PCS commencement in wk,
mean (SD)
29.2 (1.5) -
Cerebral palsyz 6 (11) 5 (5)
IQ,x mean (SD) 90.9 (16.0) 98.5 (15.2)
Data are n (%) unless otherwise specified.
*Defined as intraventricular hemorrhage grade 3 or 4 and/or cystic periventricular leukomala-
cia.
†Defined as oxygen requirement at age 36 wk.
zConfirmed at age 8 years.
xAssessed at age 18 years using the Wechsler Abbreviated Scale of Intelligence; data available
for 54 participants in the PCS group.
April 2014 ORIGINAL ARTICLESexplored using linear regression fitted using generalized esti-
mating equations with robust (sandwich) estimation of SEs
to allow for multiple births within a family, using separate
models for each brain tissue or structure. The regression
was performed first unadjusted, and then adjusted for gesta-
tional age at birth, sex, small for gestational age (birth weight
# 2 SD below the mean for their age), BPD, and major brain
injury (defined as either intraventricular hemorrhage grade 3
or 4, or cystic periventricular leukomalacia as confirmed on
neonatal cranial ultrasound). All analyses were corrected
for age at the time of the MRI. Results are presented as the
mean volumetric difference and 95% CI in cc, as well as the
percentage difference calculated as the volumetric difference
divided by themean volume of the brain tissue or structure in
the group that did not receive postnatal dexamethasone.
For brain parcel comparisons, a single mixed model was
used, combining data from all 20 regions across the 2 hemi-
spheres and using random effects to allow for the correlations
between repeated measures on an individual, fitting a sepa-
rate random effect and a separate error term within each re-
gion. Mean differences are presented as the percentage
difference relative to the mean size of the region in preterm
adolescents who did not receive postnatal dexamethasone
(using the average of the left and right measurements). All es-
timates are adjusted for corrected age at the time of the scan,
sex, and hemisphere, allowing the effect of group, sex, and
hemisphere to vary by region. We also repeated the analysis
adjusting for gestational age at birth, small for gestational
age, BPD, major brain injury, and intracranial volume.
The relationships between postnatal dexamethasone total
cumulative dose and brain volumes of the various structures
and tissues were explored in those who received postnatal
dexamethasone using linear regression, fitting a separate
model for each volume adjusted for age at MRI scan.
Results
Of the 225 extremely preterm participants known to be alive
at age 8 years, by 18 years 1 had died, 10 could not be found,
26 declined to participate, 3 were living in other states or
countries and could not attend, and 5 were too disabled to
be assessed for any component of the study, leaving 180
(80%) who were seen at 18 years of age; 162 (90% of those
who attended the 18 year follow-up) consented for the
MRI, of whom 148 (91%) were considered suitable for anal-
ysis. When we compared characteristics of participants who
did (n = 148) and did not (n = 77) have analyzable MRI, par-
ticipants who did not have the MRI were more likely to have
major brain injury (19% vs 10%, P value = .05) and cerebral
palsy confirmed at age 8 years (24% vs 8%, P value = .001),
and a lower full scale IQ at age 8 years (mean difference
[95% CI] of 6.2 [11.2, 1.1], P value = .02).
Participant characteristics for the study population are
summarized in Table II. Participants who received
postnatal dexamethasone in the newborn period were of
lower gestational age and birth weight compared withAssociation between Postnatal Dexamethasone for Treatment o
Adolescence in Infants Born Very Pretermparticipants who did not receive postnatal dexamethasone.
The proportions who were small for gestational age and
with major brain injury in the newborn period, however,
were similar in both groups. As expected, there was a
higher rate of BPD and cerebral palsy in the group who
had received postnatal dexamethasone compared with
those who did not.
Volumes of total brain tissue, cortical white matter, thal-
amus, and all nuclei of the basal ganglia were smaller in par-
ticipants who received postnatal dexamethasone compared
with those who did not, even after adjustment for gestational
age at birth, sex, small for gestational age, BPD, and presence
of major brain injury, with the exception of total brain tissue
volume, which failed to reach statistical significance
(Table III). The largest reductions, of approximately 7% in
the unadjusted analysis, were seen in the thalamus and
basal ganglia. There was little evidence of a difference in
cortical gray matter, hippocampus, amygdala, and
cerebellar volumes between the groups.
Given there was evidence of a difference in cortical white
matter between groups, we compared white matter regional
volumes between those who received postnatal dexametha-
sone and those who did not (Figure 1). There was evidence
that the effect of postnatal dexamethasone varied by region
(interaction P < .001), with a reduction in brain parcel
volumes in those receiving postnatal dexamethasone in
most of the white matter regions except the medial
temporal region. The evidence for group differences was
weaker when adjusted for gestational age at birth, sex, small
for gestational age, BPD, presence of major brain injury,
and intracranial volume.
There was weak evidence of a relationship between total
cumulative dose of postnatal dexamethasone and lower total
brain tissue volume [regression coefficient 7.7 (95%f Bronchopulmonary Dysplasia and Brain Volumes at 739
Table III. Comparison of brain volumes in participants who received postnatal dexamethasone compared with those
who did not
Brain tissue
or structure
Brain volume (cc)
mean (SD)
Mean difference
(95% CI)
P value
Adjusted mean difference*
(95% CI)
Adjusted
P value*
Postnatal
dexamethasone
(n = 55)
No postnatal
dexamethasone
(n = 93) Volume (cc) Volume (%)† Volume (cc) Volume (%)†
Total brain tissue 1262.9 (126.9) 1305.7 (126.6) 47.0 (90.7, 3.3) 3.6 (7.0, 0.3) .04 35.6 (74.5, 3.2) 2.7 (5.7, 0.2) .07
Cortical gray
matter
493.6 (48.3) 500.7 (49.9) 10.1 (26.9, 7.0) 2.0 (5.4, 1.4) .25 9.6 (24.0, 4.8) 1.9 (4.8, 1.0) .19
Cortical white
matter
422.9 (51.8) 447.0 (54.1) 23.4 (41.4, 5.4) 5.2 (9.3, 1.2) .01 19.4 (37.5, 1.4) 4.4 (8.4, 0.3) .03
Thalamus 13.6 (1.5) 14.6 (1.6) 1.1 (1.6, 0.6) 7.5 (11.0, 4.1) <.001 0.9 (1.4, 0.4) 6.0 (9.6, 2.4) .001
Basal ganglia 21.0 (2.5) 22.6 (2.5) 1.7 (2.5, 0.8) 7.5 (11.1, 3.5) <.001 1.3 (2.1, 0.5) 5.7 (9.2, 2.2) .002
Caudate 7.1 (1.1) 7.7 (1.0) 0.6 (1.0, 0.2) 7.8 (13.0, 2.6) .001 0.4 (0.8, 0.1) 5.5 (10.0, 0.9) .02
Putamen 11.0 (1.1) 11.6 (1.4) 0.7 (1.1, 0.3) 6.0 (9.5, 2.6) .001 0.6 (1.0, 0.2) 4.8 (8.4, 1.3) .007
Pallidum 2.9 (0.4) 3.3 (0.5) 0.3 (0.5, 0.2) 9.1 (15.2, 6.1) <.001 0.3 (0.5, 0.2) 9.4 (13.6, 5.2) <.001
Cerebellum 140.8 (19.5) 144.8 (16.6) 4.3 (10.5, 2.0) 3.0 (7.3, 1.4) .18 1.3 (7.1, 4.4) 0.9 (4.9, 3.0) .65
Hippocampus 8.0 (0.7) 8.1 (0.8) 0.1 (0.4, 0.1) 1.2 (4.9, 1.2) .35 0.2 (0.4, 0.1) 2.0 (4.9, 1.1) .21
Amygdala 3.3 (0.3) 3.4 (0.3) 0.1 (0.2, 0.1) 2.9 (5.9, 1.2) .20 0.1 (0.2, 0.04) 2.1 (5.6, 1.2) .21
All analysis were adjusted for age at MRI.
*Also adjusted for gestational age at birth, sex, small for gestational age, bronchopulmonary dysplasia, and major brain injury.
†Volume difference expressed as a percentage of the mean volume in the participants who did not receive postnatal dexamethasone for the particular brain tissue or structure.
THE JOURNAL OF PEDIATRICS  www.jpeds.com Vol. 164, No. 4CI16.2, 0.8), R2 0.06, P value = .08] (Figure 2) and cortical
white matter [regression coefficient3.2 (95% CI6.6, 0.2),
R2 0.10, P value = .06]. There was little evidence of a
relationship between total cumulative dose of postnatal
dexamethasone and the volumes of other brain tissues or
structures (all P > .1, data not shown).Figure 1. Mean differences (95% CI) in cortical white matter volu
compared with preterm infants who did not receive postnatal dex
corrected age at the time of the scan, sex, and hemisphere, allow
Adjusted estimates are also adjusted for gestational age at birth,
neonatal brain injury, and intracranial volume.
740Discussion
Postnatal dexamethasone use to treat or prevent BPD in the
newborn period was associated with smaller brain volumes in
total brain tissue, cortical white matter, thalamus, and all
nuclei of the basal ganglia at age 18 years in a largeme in preterm infants who received postnatal dexamethasone
amethasone at 18 years of age. All estimates are adjusted for
ing the effect of group, sex, and hemisphere to vary by region.
small for gestational age, bronchopulmonary dysplasia,
Cheong et al
Figure 2. Relationship between total brain tissue volume and
cumulative postnatal dexamethasone dose. Regression co-
efficient 7.7 (95% CI 16.2, 0.8), R2 0.06, P value = .08.
April 2014 ORIGINAL ARTICLESgeographical cohort of extremely preterm adolescents.
Smaller white matter volumes associated with postnatal
dexamethasone use reflect a global reduction across the ma-
jority of the white matter regions. Contrary to previous
short-term outcome studies,8,9,12 we did not find that post-
natal dexamethasone use was associated with reductions in
cortical gray matter or cerebellar volumes. We also found
that the total dose of postnatal dexamethasone was weakly
associated with lower volumes of total brain tissue and
cortical white matter in those who received postnatal dexa-
methasone.
Brain volume alterations associated with postnatal dexa-
methasone have been reported at term equivalent age, most
consistently for total brain tissue, cortical gray matter, and
the cerebellum. Previous small studies have reported smaller
total brain tissue and cortical gray matter in the order of
10%-30% in a study of 7 preterm infants treated with dexa-
methasone compared with 11 non-treated preterm infants,
and of 9%-35% in 11 preterm infants treated with dexameth-
asone compared with 30 non-treated preterm infants.8,9 The
study reporting the largest differences in brain volumes with
postnatal dexamethasone use did not adjust for gestational
age at time of MRI scan or other potential confounders,
and the infants had received a wide range of steroid doses
[mean duration (SD) of 28 (22) days, median dose of 0.25
mg/kg/d (range: 0.19-0.90 mg/kg/d)].8 A larger study did
not find differences in total brain tissue volume at term
equivalent age in 123 participants who received an MRI
scan at term equivalent age, in groups who received either
dexamethasone (n = 17) or hydrocortisone (n = 28)
compared with those who received no PCS.12 In the current
study, we found approximately 3% smaller total brain tissue
volume at age 18 years in those who received postnatal dexa-
methasone, even after adjustment for potential confounders.
The fact that the magnitude of difference varies between
studies may reflect inherent differences in cohort characteris-Association between Postnatal Dexamethasone for Treatment o
Adolescence in Infants Born Very Pretermtics, as well as different corticosteriod dosing regimens used.
Our findings lend support to the hypothesis that the associ-
ation between postnatal dexamethasone use and smaller
brain volumes, noted as early as term equivalent age, persists
into adolescence, with varying effects in the different brain
tissues and regions.
Contrary to previous studies, we did not find evidence of
smaller cerebellar volumes at age 18 years with postnatal
dexamethasone use.7 Experimental models have demon-
strated deleterious effects on the granule cells of the cere-
bellum with respect to decreased proliferation and
increased apoptosis.23,24 Parikh et al9 reported a 21%
decrease in cerebellar size at term equivalent age in extremely
low birth weight (birthweight <1000 g) infants who had
received a mean cumulative dose of 2.8 mg/kg of dexameth-
asone (n = 11) compared with those who received no dexa-
methasone (n = 30). In another cohort study of 172 babies
with a mean gestational age 28 weeks, there were 8% and
10% reductions in cerebellar volumes by 40 weeks post-
menstrual age in infants who had received postnatal hydro-
cortisone (median dose 14 mg/kg) and dexamethasone
(median dose 1.2 mg/kg) compared with no PCS use, respec-
tively.12 The absence of cerebellar volume difference in
adolescence in our study, despite having used higher doses
of dexamethasone compared with the 2 studies above, sug-
gests that there may have been ‘catch-up’ growth of the cer-
ebellum in the early years after birth.
In the current study, we found the largest relative volume
differences associated with postnatal dexamethasone use in
the thalamus and basal ganglia, and to a lesser extent, the
cortical white matter. Glucocorticoid receptors have been
identified in the posterior thalamus, and corticosteroids
have been shown in experimental models to exert effects on
these receptors within the thalamus.25 Thus, thalamic vol-
ume reductions related to postnatal dexamethasone use is
plausible. White matter volume reductions related to post-
natal dexamethasone have not been reported in previous
studies of younger subjects.8-11,13 The volume effects of post-
natal dexamethasone on different brain tissues or structures
compared with studies performed at term equivalent age
may reflect vulnerability of specific brain tissues or structures
to postnatal dexamethasone and altered trajectory of devel-
opment that do not become evident until late adolescence.
In addition, we were able to demonstrate that the smaller
white matter volumes reflected a global change, rather than
vulnerability of specific white matter regions, with the excep-
tion of larger white matter volumes in the medial temporal
region following postnatal dexamethasone use for reasons
that are unclear.
There has been much interest in alternative corticosteroids
such as hydrocortisone to prevent or treat BPD. At both term
equivalent age and also at age 8 years, several studies
comparing hydrocortisone-treated preterm infants with pre-
term infants who received no hydrocortisone reported little
evidence of differences in volumes of total brain tissue,
cortical gray matter, white matter, deep nuclear gray matter,
cerebellum, and hippocampus10,11,26; only 1 of these studiesf Bronchopulmonary Dysplasia and Brain Volumes at 741
THE JOURNAL OF PEDIATRICS  www.jpeds.com Vol. 164, No. 4was a randomized-controlled trial.26 All the studies used hy-
drocortisone doses that were much lower than the mean 7.9
mg/kg dexamethasone-equivalent dose used in the current
study. One study comparing ex-preterm 8-year-olds who
received hydrocortisone or not also reported similar mean
intelligence.11 None of these previous studies were able to
confirm that there was any effect of postnatal hydrocortisone
on pulmonary outcomes like BPD. In contrast, a larger study
documented smaller cerebellar volumes at term equivalent
age in infants who had received hydrocortisone compared
with those who had not, although the magnitude of differ-
ence was less than that observed in infants who had received
dexamethasone.12 The “hydrocortisone” group in that study
did not exclusively receive hydrocortisone as some of the in-
fants also received dexamethasone. There is experimental ev-
idence suggesting that hydrocortisone may be less neurotoxic
to the brain than dexamethasone, relating to the fact that
hydrocortisone preferentially binds to mineralocorticoid
receptors rather than glucocorticoid receptors such as dexa-
methasone.27 Activation of glucocorticoid receptors has been
associated with neuronal apoptosis in the hippocampus and
cerebellum.3,4,23,24 However, the efficacy of hydrocortisone
in preventing or treating BPD has not been definitively
demonstrated in randomized-controlled trials.28
The current study has several strengths. We report findings
from a large geographical cohort of extremely preterm in-
fants, prospectively followed up from birth. A high percent-
age of participants who attended the 18-year follow-up
consented for the MRI.
We also acknowledge the limitations. Participants who
did not have an MRI were more likely to have major brain
injury and cerebral palsy, which may have affected the abil-
ity to detect differences in brain tissue volumes between the
groups. As the MRI data are cross-sectional, we were not
able to infer any developmental changes in brain volume
from an earlier age. Brain MRI was not available for
neonatal research in 1991-1992, when the study participants
were born. It is also important to note that the findings of
the current study relate to postnatal dexamethasone pre-
scribing practices dating back 18 years. Since then, lower
doses of dexamethasone have been used and proportionally
fewer extremely preterm subjects have been treated with
dexamethasone in the state of Victoria.29 Given the non-
random allocation of babies to postnatal dexamethasone,
we describe an association, albeit a robust one, between
postnatal dexamethasone and reduced brain growth, rather
than infer causality.
Postnatal dexamethasone use in the newborn period in
extremely preterm infants is associated with brain volume re-
ductions in adolescence, particularly total brain tissue,
cortical white matter, thalamus, and basal ganglia. This high-
lights potential vulnerability of the brain to dexamethasone
that persist into adolescence. Although there is a suggestion
that alternative PCS like hydrocortisone is not associated
with alterations in brain size, studies to date are relatively
short-term with limited information on functional neurode-
velopmental correlates. Future studies should include clarifi-742cation of long-term brain alterations in association with
functional outcomes of preterm infants using alternative
PCS or lower dose regimens of dexamethasone. n
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Table I. Twenty brain parcellated regions derived from the 34 regions generated from the automated Freesurfer
program1
Brain lobes Freesurfer-generated brain regions Brain region labels used for this study
Frontal Postcentral gyrus Postcentral
Precentral gyrus Precentral
Superior frontal gyrus Superior frontal
Middle frontal gyrus (caudal + rostral division) + frontal pole Middle frontal
Pars opercularis + pars triangularis Inferior frontal
Pars orbitalis + orbitofrontal cortex (lateral + medial division) Orbital frontal
Temporal Superior temporal gyrus + transverse temporal cortex Superior temporal
Middle temporal gyrus + banks of the superior temporal sulcus Lateral temporal
Inferior temporal gyrus + fusiform gyrus Inferior temporal
Temporal pole + entorhinal cortex + Parahippocampal gyrus Medial temporal
Parietal Inferior parietal cortex + superior parietal cortex Lateral parietal
Supramarginal gyrus Supramarginal
Cuneus cortex + precuneus cortex + Paracentral Lobule Medial occipital parietal
Occipital Lateral occipital cortex Lateral occipital
Lingual gyrus + pericalcarine cortex Medial occipital
Other Cingulate cortex - rostral anterior division Rostral anterior cingulate
Cingulate cortex - caudal anterior division Caudal anterior cingulate
Cingulate cortex - posterior division Posterior cingulate
Cingulate cortex - isthmus division Isthmus
Insula Insula
Appendix
Additional members of the Victorian Infant Collaborative
Study Group include:
Premature Infant Follow-up Program at the Royal
Women’s Hospital, Melbourne, Australia: Catherine Call-
anan, RN, Esther Hutchinson, BSc (Hons), Marion McDo-
nald, RN, Karissa Searle, BSc; Premature Infant Follow-up
Program at the Royal Women’s Hospital and Obstetrics
and Gynecology, the University of Melbourne, Melbourne,
Australia: Cinzia R. De Luca, BSc, PhD, Carly Molloy,
PhD, Michelle Wilson-Ching, PhD; Premature Infant
Follow-up Program at the Royal Women’s Hospital and
Mercy Hospital for Women, Melbourne, Australia: Elaine
Kelly, MA; Monash Medical Centre, Melbourne, Australia:
Elizabeth Carse, FRACP, Margaret P. Charlton, M Ed Psych,
Marie Hayes, RN; Mercy Hospital for Women, Melbourne,
Australia: Gillian Opie, FRACP, Andrew Watkins, FRACP,
Amanda Williamson, Heather Woods, RN; and Royal Chil-
dren’s Hospital, Melbourne, Australia: Colin Robertson,
MD, FRACP (funded by Australian National Health and
Medical Research Council [491246].
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